Merrimack develops bispecific against c-MET oncogene

Merrimack has overcome hurdles to antibody targeting of c-MET with a bispecific that increases avidity by anchoring to a tumor surface protein.

Marketed small molecules inhibiting c-MET, which

Read the full 272 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE